News
PHVS
17.23
+1.06%
0.18
Pharvaris initiated with a Buy at Guggenheim on HAE potential
TipRanks · 1d ago
Pharvaris initiated with a Buy at Guggenheim
TipRanks · 1d ago
Pharvaris Announces 2025 Annual Shareholders Meeting Amidst Phase 3 Trials
TipRanks · 2d ago
Pharvaris Announces Annual Meeting of Shareholders
Barchart · 3d ago
Morgan Stanley Reaffirms Their Buy Rating on Pharvaris (PHVS)
TipRanks · 3d ago
Weekly Report: what happened at PHVS last week (0602-0606)?
Weekly Report · 4d ago
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), aTyr Pharma (ATYR) and Pharvaris (PHVS)
TipRanks · 4d ago
Wedbush Keeps Their Buy Rating on Pharvaris (PHVS)
TipRanks · 06/05 14:45
Pharvaris Price Target Maintained With a $27.00/Share by Wedbush
Dow Jones · 06/05 13:44
Wedbush Reiterates Outperform on Pharvaris, Maintains $27 Price Target
Benzinga · 06/05 13:34
Oppenheimer Remains a Buy on Pharvaris (PHVS)
TipRanks · 06/05 12:37
Citizens JMP Sticks to Their Buy Rating for Pharvaris (PHVS)
TipRanks · 06/05 11:36
Pharvaris’s Strategic Advancements and Clinical Progress Justify Buy Rating
TipRanks · 06/05 10:25
Bank of America Securities Sticks to Its Sell Rating for Pharvaris (PHVS)
TipRanks · 06/05 08:55
Pharvaris Presents Key Findings On Bradykinin B2 Antagonists At Angioedema Workshop
Benzinga · 06/02 10:51
Weekly Report: what happened at PHVS last week (0526-0530)?
Weekly Report · 06/02 09:21
Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema
Barchart · 06/02 05:50
Pharvaris (PHVS) Gets a Buy from Morgan Stanley
TipRanks · 05/27 12:27
Weekly Report: what happened at PHVS last week (0519-0523)?
Weekly Report · 05/26 09:21
Pharvaris (PHVS) Receives a Buy from Morgan Stanley
TipRanks · 05/19 12:47
More
Webull provides a variety of real-time PHVS stock news. You can receive the latest news about Pharvaris N.V. through multiple platforms. This information may help you make smarter investment decisions.
About PHVS
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.